TYRA BIOSCIENCES, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $102.9M | $80.1M | $62.5M | $43.0M | $20.6M | $7.2M |
| SG&A Expense | — | $29.8M | $24.1M | $17.4M | $15.9M | $5.7M | $2.1M |
| Operating Income | — | $-132.8M | $-104.2M | $-79.9M | $-58.9M | $-26.3M | $-9.3M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $2.0K | $1.0K | $1.0K |
| Net Income | — | $-119.9M | $-86.5M | $-69.1M | $-55.3M | $-26.3M | $-9.3M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-2.01 | $-1.51 | $-1.62 | $-1.32 | $-0.64 | $-2.02 |
| EPS (Diluted) | — | $-2.01 | $-1.51 | $-1.62 | $-1.32 | $-0.64 | $-2.02 |
| Shares Outstanding (Basic) | 53.9M | 59.6M | 57.2M | 42.7M | 41.9M | 41.3M | 5.5M |
| Shares Outstanding (Diluted) | 53.9M | 59.6M | 57.2M | 42.7M | 41.9M | 41.3M | 5.5M |
| Dividends Per Share | — | — | — | — | — | — | — |